Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR5A | P47898 | 2/20 | 0.40 |
| ▸ | BRD4 | O60885 | 3/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.38 |
| ▸ | AR | P10275 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | EP300 | Q09472 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | PNMT | P11086 | 1/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30681298 | 0.86 | LMNA (0.46) | ACHEHTR2AHTR2CHTR5ABRD4 | |
| SCHEMBL8937088 | 0.86 | LMNA (0.46) | ACHEHTR2AHTR2CHTR5ABRD4 | |
| SCHEMBL29529402 | 0.86 | LMNA (0.46) | ACHEHTR2AHTR2CHTR5ABRD4 | |
| SCHEMBL4102066 | 0.81 | HTR2C (0.44) | ACHEHTR2AHTR2CHTR5AAR | |
| SCHEMBL21782466 | 0.78 | ACHE (0.43) | ACHEHTR2AHTR2CHTR5ABRD4 | |
| SCHEMBL7920989 | 0.78 | ACHE (0.43) | ACHEHTR2AHTR2CHTR5ABRD4 | |
| SCHEMBL7897325 | 0.76 | CMA1 (0.43) | HTR2AHTR2CHTR5ABRD4CREBBP | |
| SCHEMBL94115 | 0.76 | ESR2 (0.49) | BRD4CREBBPTSHREP300LMNA | |
| SCHEMBL8525664 | 0.76 | BRD4 (0.38) | BRD4CREBBPARTSHREP300 | |
| SCHEMBL30697867 | 0.76 | PNMT (0.62) | HTR2AHTR2CADRA2APNMTADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2658844-B1 | NOVEL PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI SA (FR) | 2016-10-26 | — | — | EP | disclosed |
| EP-2658844-B1 | NOVEL PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI SA (FR) | 2016-10-26 | — | — | EP | disclosed |
| US-9133168-B2 | Pyrimidine derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors | SANOFI (FR) | 2015-09-15 | — | — | US | disclosed |
| US-9133168-B2 | Pyrimidine derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors | SANOFI (FR) | 2015-09-15 | — | — | US | disclosed |
| US-9133168-B2 | Pyrimidine derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors | SANOFI (FR) | 2015-09-15 | — | — | US | disclosed |
| EP-1829872-B1 | PROCESSES FOR PRODUCTION OF INDOLE COMPOUNDS | NISSAN CHEMICAL IND LTD (JP) | 2015-07-29 | — | — | EP | disclosed |
| US-20130274253-A1 | NOVEL PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI (FR) | 2013-10-17 | — | — | US | disclosed |
| US-20130274253-A1 | NOVEL PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI (FR) | 2013-10-17 | — | — | US | disclosed |
| US-20130274253-A1 | NOVEL PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI (FR) | 2013-10-17 | — | — | US | disclosed |
| CN-101468964-B | Processes for producing indole compound | NISSAN CHEMICAL IND LTD | 2011-05-11 | — | — | CN | disclosed |
| US-20100197938-A1 | Process for producing indole compoud | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-08-05 | — | — | US | disclosed |
| CN-100577659-C | Processes for producing indole compound | NISSAN CHEMICAL IND LTD | 2010-01-06 | — | — | CN | disclosed |
| CN-101468964-A | Processes for producing indole compound | NISSAN CHEMICAL IND LTD (JP) | 2009-07-01 | — | — | CN | disclosed |
| EP-1829872-A1 | PROCESSES FOR PRODUCTION OF INDOLE COMPOUNDS | Nissan Chemical Industries, Ltd. (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-20070083053-A1 | Process for producing indole compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2007-04-12 | — | — | US | disclosed |
| CN-1896075-A | Processes for producing indole compound | NISSAN CHEMICAL IND LTD (JP) | 2007-01-17 | — | — | CN | disclosed |
| CN-1286832-C | Process for producing indole compound | NISSAN CHEMICAL IND LTD (JP) | 2006-11-29 | — | — | CN | disclosed |
| CN-1646522-A | Process for producing indole compound | NISSAN CHEMICAL IND LTD (JP) | 2005-07-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274253-A1 | NOVEL PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | TYMP, PIK3CA, PDPK1 | ACHE 3761/4885HTR2A 2904/4885HTR2C 3622/4885 |
| US-20100197938-A1 | Process for producing indole compoud | IDO1, IDO2, NOS2 | ACHE 695/4885HTR2A 57/4885HTR2C 78/4885 |
| US-20070083053-A1 | Process for producing indole compound | IDO2, IDO1, TDO2 | ACHE 268/4885HTR2A 45/4885HTR2C 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.